Delirium: scope consultation
NICE have been asked to develop a clinical practice guideline on the diagnosis, prevention and management of delirium for use in the NHS in England and Wales. The draft scope defines what aspects of care the guideline will cover and to whom it will apply. Registered stakeholders for this guideline are invited to submit comments on the scope and may suggest clinical questions that could be answered in the guideline.
Although individuals and organisations not registered as stakeholders are able to comment, we recommend that you contact the registered stakeholder organisation that most closely represents your interests and pass your comments to them. We work closely with stakeholder organisations and take their views very seriously.
Consultation dates: 16 April 2008 - 14 May 2008
Consultation documents:
How to submit your comments:
Please use the comments proforma and return by email to delirium@nice.org.uk or on a disk to:
Guidelines Coordinator
Centre for Clinical Practice
National Institute for Health and Clinical Excellence
MidCity Place
71 High Holborn
London
WC1V 6NA
The Institute is unable to accept:
- more than one response per stakeholder organisation
- comments received after the consultation deadline
- comments that are not on the correct proforma
- confidential information or other material that you would not wish to be made public
- personal medical information about yourself or another person from which your or the person?s identity could be ascertained.
What will happen to your comments:
- All comments (with the exception of personal, individual comments and late comments) will be sent to the developers at the end of the consultation
- Comments from registered stakeholders and nominated expert reviewers ONLY will be formally responded to by the developers and posted on the NICE website after the final guideline is published
- No action will be taken upon receipt of personal, individual comments and late comments.
Acknowledgement of comments:
You should receive an automated acknowledgement from the email box when you email your comments. If you do not receive this acknowledgement, please contact the relevant Guidelines Coordinator to ensure your comments have been safely received.
Consultation on draft guideline: 14 October - 9 December 2009
Anticipated publication date: April 2010
Further information
This page was last updated: 30 March 2010
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
Appendix D diagnostic test accuracy - included studies (PDF 182 KB)
-
-
Appendix D non pharmacological risk factors - included studies (PDF 90 KB)
-
Appendix D pharmacological risk factors - included studies (PDF 49 KB)
-
Appendix E consequences of cohort studies - methodological quality (PDF 125 KB)
-
Appendix E diagnostic accuracy tests - methodological quality (PDF 172 KB)
-
Appendix E epidemiology - methodological quality (PDF 168 KB)
-
Appendix E non-pharmacological risk factors cohort studies - methodological quality (PDF 44 KB)
-
Appendix E pharmacological risk factors cohort studies - methodological quality (PDF 29 KB)
-
Appendix E patient information - methodological quality (PDF 213 KB)
-
Appendix F consequences of - multivariate risk factors (PDF 185 KB)
-
Appendix F - non-pharmacological risk factors - multivariate risk factors (PDF 293 KB)
-
Appendix F pharmacological risk factors - multivariate risk factors (PDF 63 KB)
-
Appendix G diagnostic test accuracy - excluded studies (PDF 128 KB)
-
Appendix G adverse effects review - excluded studies (PDF 121 KB)
-
-
Appendix G epidemiology review - excluded studies (PDF 146 KB)
-
Appendix G non-pharmacological risk factors - excluded studies (PDF 71 KB)
-
Appendix G information for patients review - excluded studies (PDF 118 KB)
-
Appendix G pharmacological risk factors - excluded studies (PDF 55 KB)
-
-
-
-
-
Consultation table and with developers responses (PDF 1.02 MB)
-
Pre-publication check - stakeholder comments/developer responses (PDF 49 KB)
-
-
-
-
-
Appendix D - Adverse Effects - Included studies (PDF 121 KB)
-
Appendix D - Consequences of - Included studies (PDF 155 KB)
-
Appendix D - Diagnostic Test Accuracy - Included Studies (PDF 182 KB)
-
-
Appendix D - Non pharmacological Risk factor - Included studies (PDF 44 KB)
-
Appendix D - Pharma Nonpharma Prevention Treatment - Included studies (PDF 170 KB)
-
Appendix D - Pharmacological Risk factors - Included studies (PDF 49 KB)
-
-
Appendix E - Diagnostic Accuracy Tests Methodological Quality (PDF 172 KB)
-
-
-
-
Appendix E - Pharma NonPharma Prevention Treatment (PDF 107 KB)
-
Appendix E - Pharmacological Risk Factors review - Randomised controlled trials (PDF 23 KB)
-
Appendix E - Pharmacological Risk Factors review - cohort studies (PDF 30 KB)
-
-
Appendix H - Recommendations for Future Research (PDF 75 KB)
-
-
-
-
Consultation table and with developers responses (PDF 1.02 MB)